Cullinan Therapeutics CGEM Cash Flow Statement (2020-2026)

NASDAQ CGEM
$22.17 +0.01 (+0.05%)
As of: Sep 4, 2026 · 2:25 PM EDT
Reported Financials

Cullinan Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Cullinan Therapeutics reported cash from operations of -$38.22M and free cash flow of -$38.22M for the quarter ended Jun 2026, up 33.7% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-18.26M-34.21M-12.86M174.06M-24.89M-27.07M-58.14M-32.21M-39.18M-25.56M-37.30M-41.96M-40.47M-47.54M-48.42M-69.87M-50.50M-50.64M-49.60M-53.61M
Share-based Compensation
4.62M12.14M6.57M8.61M5.27M7.51M7.26M7.92M7.74M7.52M8.23M10.53M9.43M9.63M9.37M9.89M9.47M7.31M7.62M8.45M
Deferred Taxes
-19.57M
Asset Writedowns and Impairment
0.40M
Cash from Operations
-10.55M-15.17M-21.91M-25.42M-54.35M-24.98M-51.00M-31.01M-34.14M-18.13M-38.25M-36.29M-34.14M-36.63M-43.16M-57.61M-36.88M-38.11M-46.05M-38.22M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization
0.01M0.01M0.01M0.01M0.01M0.06M0.07M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M0.08M
Change in Working Capital
Change in Account Payables
0.52M1.15M3.14M-3.21M-1.58M1.15M-0.63M0.46M-1.54M1.54M1.21M-2.15M0.56M-0.43M1.72M-0.94M-0.74M-0.88M1.67M1.22M
Change in Accured Expenses
1.60M2.77M1.03M4.69M1.23M1.58M2.64M-2.82M5.17M5.06M-7.53M3.60M-0.06M6.89M-5.25M1.61M5.49M6.18M-4.31M4.21M
Change in Taxes
46.50M-35.10M-7.12M-0.07M-4.21M
Other Working Capital Changes
-0.10M-1.83M1.14M-0.09M-0.54M0.62M0.76M-1.92M3.81M3.29M-0.41M2.59M-1.34M1.64M-1.74M-3.52M-0.80M-0.84M0.66M-2.09M
Investing Activities
Capital Expenditures
0.25M0.88M0.16M0.05M0.01M
Change in Acquisitions & Divestments
59.71M61.40M91.73M67.20M61.40M132.60M104.48M93.61M93.82M117.48M144.32M139.82M116.67M184.00M162.65M131.93M80.00M42.00M52.55M55.25M
Cash from Investing Activities
-25.59M-15.86M34.71M300.85M-57.98M-28.61M15.18M12.11M-42.96M51.47M12.96M-185.11M19.88M15.96M36.80M53.40M67.39M22.39M32.41M40.68M
Financing Activities
Other financing activities
1.15M
Debt Issuance and Repayment
Long-Term Debt Issuances
0.80M1.40M
Change in Capital Stock
Net Shares Issued and Repurchased
5.48M2.89M2.09M3.00M2.73M
Net Equity Issued and Repurchased
0.58M2.70M1.59M0.61M0.17M1.82M36.56M262.65M
Dividend Payments
Dividends Paid - Common
3.79M0.66M
Misc.
Cash from Financing Activities
0.58M2.70M3.54M2.01M1.43M-32.91M1.79M38.60M0.11M0.25M1.08M262.20M1.32M1.58M0.37M0.71M0.38M1.10M
Change in Cash
-35.56M-28.33M16.34M277.44M-110.91M-86.50M-34.02M19.71M-76.99M33.59M-24.21M40.79M-12.94M-19.08M-6.35M-3.83M30.52M-15.00M-13.25M3.56M
Free Cash Flow
-10.55M-15.17M-21.91M-25.42M-54.60M-25.86M-51.16M-31.05M-34.14M-18.13M-38.25M-36.29M-34.14M-36.63M-43.16M-57.61M-36.88M-38.12M-46.05M-38.22M
Net Cash Flow
-35.56M-28.33M16.34M277.44M-110.91M-86.50M-34.02M19.71M-76.99M33.59M-24.21M40.79M-12.94M-19.08M-6.35M-3.83M30.52M-15.00M-13.25M3.56M